$ALX

Alexander’s Completes Sale of Rego Park I

Alexander’s, Inc. (NYSE: ALX) said it completed the sale of its Rego Park I property in Queens, New York, to Northwell Health. The gross price was $235.5 million and net proceeds were $203 million; it received $224 million at closing after paying $21 million of costs. The company expects a ~$148 million financial statement gain in Q2 and ~$145 million tax gain, with $48 million in 2025 and ~$97 million in 2026.

Original reporting
Published May 28, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 28, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alexander’s Completes Sale of Rego Park I — source image
Decision brief

The 30-second read

$ALXBullishMed
01

Why it matters

Completion confirms deal economics and provides explicit accounting/tax gain timing, which should feed directly into Q2 financial modeling and guidance expectations.

02

Market read

A completed, large NYC property sale with specified Q2 gain recognition is a concrete catalyst for ALX’s near-term earnings narrative.

03

What to watch

Traders may discount the impact if ALX’s core FFO/recurring earnings are unchanged and if proceeds are not clearly tied to accretive reinvestment or debt reduction.

Relevance 9/10Novelty 8/10Timing: After-hours/overnight—gain recognition scheduled for Q2

Background

Alexander’s is a NYC-focused REIT; it previously announced the sale of its Rego Park I property in Queens to Northwell Health.

Company-level read

Ticker impact

$ALXBullishMedium confidence
Context

Alexander’s completed the sale of Rego Park I to Northwell Health, locking in $235.5M gross price and ~$148M gain to Q2 results.

Expected impact

Near-term support for ALX as investors model the Q2 gain; limited upside beyond expectations if already priced in.

Evidence & confidence

The article provides concrete deal economics (gross/net proceeds) and explicit timing for gain recognition (Q2), which can directly affect reported earnings and REIT performance metrics.

Market effects

Reinforces that NYC REIT asset sales can crystallize large gains, potentially supporting sector sentiment around monetization of stabilized assets.

Highlights continued demand for NYC healthcare-linked real estate (buyer: Northwell Health) in Queens.

Low—primarily company-specific asset monetization with limited cross-border read-across.

Counterpoint

If the gain is largely non-cash or tax-driven, equity reaction may be muted versus what headline gain suggests.

Key entities

  • Alexander’s, Inc.

    NYC REIT completing the Rego Park I property sale.

  • Northwell Health, Inc.

    Healthcare system purchasing Rego Park I property.

Related articles

$ALXMed

Are Atlas Arteria Shares Overvalued? The Street View

Atlas Arteria (ASX: ALX) shares are up 4.72% YTD and trade around A$5.10, with a ~7% dividend yield. RBC Capital Markets downgraded the stock to Underperform and set a A$4.75 price target, citing liquidity concerns as IFM Investors’ hostile bid nears 40–45% and risks to distribution sustainability. IFM’s offer is A$4.75, rising to A$5.10 at 45% ownership.

$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

$CSCOMed

Cisco Stock Is Finally Pricing In A New Growth Story

Cisco raised full-year revenue and EPS guidance on May 13, 2026, citing AI infrastructure demand. Management expects about $9 billion in FY2026 AI orders from hyperscalers and cited 5 hyperscaler design wins in Q3. Cisco shares rose about 20% since, with product orders up 19% YoY excluding hyperscaler growth. Options imply 41% IV ahead of the next catalyst.

$RMDMed

Off Into Weekend, As Early Work Undone

ResMed (ASX:RMD) fell 8.29% on Friday and is 3.09% lower for the week after a strong run. The company reported a solid Q4, with FY26 revenue up 10% to $5.7b, gross Q4 margin 62.3%, FY EPS up 17% to $11.17, and a 10% dividend increase to $0.66. Morgan Stanley downgraded to Equal Weight and cut its price target, citing cooling growth and Philips’ potential US return in 2027.